JOURNAL OF PROSTHETIC DENTISTRY THE

Vol. 101 No. 5      May - 2009

ISSN: 0022-3913      UBIC: 171

RESUMEN

Orally administered bisphosphonates are generally considered a first-line medication for treatment of osteoporosis. As side effect of bisphosphonates, osteonecrosis of the jaws (ONJ) has been reported worldwide. Most reports of necrosis are attributed to the use of bisphosphonates administered intravenously for the treatment of bone disorders such as multiple myeloma. However, osteonecrosis has also been diagnosed in patients receiving oral bisphosphonates. The management of a patient with spontaneous removable partial denture prosthesis-related ONJ associated with short-term oral administration of bisphosphonate is described. (J Prosthet Dent 2009;1 01:289-292)

SUMMARY

Oral bisphosphonates increase the risk for ONJ, which can develop after a relatively short-term oral administration. IfONJ is discovered at an early stage, it may be successfully treated noninvasively. The ONJ of the patient presented could be treated conservatively, by frequent gargling with povidone iodine and removal of the irritant (the RPD); surgical intervention was not required. However, because of the possibility of ONJ recurrence, dentists must provide long-term recall and procedures for its prevention.

| Volver |